![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
NE Kaminski, ME Abood, FK Kessler, BR Martin and AR Schatz
Department of Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298.
Extensive behavioral and biochemical characterization of cannabinoid- mediated effects on the central nervous system has revealed at least three lines of evidence supporting the role of a putative guanine nucleotide-binding protein-coupled cannabinoid receptor for cannabimimetic effects, (i) stereoselectivity, (ii) inhibition of the adenylate cyclase/cAMP second messenger system, and (iii) radioligand- binding studies with the synthetic cannabinoid [3H]CP-55,940 indicating a high degree of specific binding to brain tissue preparations. Based on recent findings from our laboratory demonstrating that delta 9- tetrahydrocannabinol markedly inhibited forskolin-stimulated cAMP accumulation in mouse spleen cells, the presence of a guanine nucleotide-binding protein-coupled cannabinoid receptor associated with mouse spleen cells and its functional role in immune modulation were investigated. In the present studies, stereoselective immune modulation was observed with the synthetic bicyclic cannabinoid (-)-CP-55,940 versus (+) CP-56,667 and with 11-OH-delta 8-tetrahydrocannabinol- dimethylheptyl, (-)-HU-210 versus (+)-HU-211. In both cases, the (-)- enantiomer demonstrated greater immunoinhibitory potency than the (+)- isomer, as measured by the in vitro sheep red blood cell antibody- forming cell response. Radioligand binding studies produced a saturation isotherm exhibiting approximately 45-65% specific binding to mouse spleen cells. Scatchard analysis demonstrated a single binding site on spleen cells, possessing a Kd of 910 pM and a Bmax of approximately 1000 receptors/spleen cell. RNA polymerase chain reaction of isolated splenic RNA using specific primers for the cannabinoid receptor resulted in the amplification of a 854-kilobase predicted product that hybridized with cannabinoid receptor cDNA, demonstrating the presence of cannabinoid receptor mRNA in mouse spleen. Together, these findings strongly support the role of a cannabinoid receptor in immune modulation by cannabimimetic agents.
This article has been cited by other articles:
|
|
 |
|
  H. B. Bradshaw, N. Rimmerman, J. F. Krey, and J. M. Walker Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2006; 291(2): R349 - R358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor {gamma} Independently of Cannabinoid Receptors 1 and 2 Mol. Pharmacol., July 1, 2006; 70(1): 101 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Raduner, A. Majewska, J.-Z. Chen, X.-Q. Xie, J. Hamon, B. Faller, K.-H. Altmann, and J. Gertsch Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS J. Biol. Chem., May 19, 2006; 281(20): 14192 - 14206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. H. Habayeb, A. H. Taylor, M. D. Evans, M. S. Cooke, D. J. Taylor, S. C. Bell, and J. C. Konje Plasma Levels of the Endocannabinoid Anandamide in Women--A Potential Role in Pregnancy Maintenance and Labor? J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5482 - 5487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Rockwell and N. E. Kaminski A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 683 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Klein, C. Newton, K. Larsen, L. Lu, I. Perkins, L. Nong, and H. Friedman The cannabinoid system and immune modulation J. Leukoc. Biol., October 1, 2003; 74(4): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Samson, A. Small-Howard, L. M. N. Shimoda, M. Koblan-Huberson, A. J. Stokes, and H. Turner Differential Roles of CB1 and CB2 Cannabinoid Receptors in Mast Cells J. Immunol., May 15, 2003; 170(10): 4953 - 4962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Breivogel, G. Griffin, V. Di Marzo, and B. R. Martin Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain Mol. Pharmacol., July 1, 2001; 60(1): 155 - 163. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. K. Mani, A. Mitchell, and B. W. O'Malley Progesterone receptor and dopamine receptors are required in Delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats PNAS, January 23, 2001; (2001) 31563998. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. W. Klein, B. Lane, C. A. Newton, and H. Friedman The Cannabinoid System and Cytokine Network Experimental Biology and Medicine, October 1, 2000; 225(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
J.-M. Derocq, O. Jbilo, M. Bouaboula, M. Segui, C. Clere, and P. Casellas Genomic and Functional Changes Induced by the Activation of the Peripheral Cannabinoid Receptor CB2 in the Promyelocytic Cells HL-60. POSSIBLE INVOLVEMENT OF THE CB2 RECEPTOR IN CELL DIFFERENTIATION J. Biol. Chem., May 19, 2000; 275(21): 15621 - 15628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Gonsiorek, C. Lunn, X. Fan, S. Narula, D. Lundell, and R. W. Hipkin Endocannabinoid 2-Arachidonyl Glycerol Is a Full Agonist through Human Type 2 Cannabinoid Receptor: Antagonism by Anandamide Mol. Pharmacol., May 1, 2000; 57(5): 1045 - 1050. [Abstract] [Full Text]
|
|
|
|
|
|
G. Griffin, Q. Tao, and M. E. Abood Cloning and Pharmacological Characterization of the Rat CB2 Cannabinoid Receptor J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 886 - 894. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Yea, K.-H. Yang, and N. E. Kaminski Role of Nuclear Factor of Activated T-Cells and Activator Protein-1 in the Inhibition of Interleukin-2 Gene Transcription by Cannabinol in EL4 T-Cells J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 597 - 605. [Abstract] [Full Text]
|
|
|
|
|
|
T. Sugiura, S. Kondo, S. Kishimoto, T. Miyashita, S. Nakane, T. Kodaka, Y. Suhara, H. Takayama, and K. Waku Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor. COMPARISON OF THE AGONISTIC ACTIVITIES OF VARIOUS CANNABINOID RECEPTOR LIGANDS IN HL-60 CELLS J. Biol. Chem., January 7, 2000; 275(1): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rinaldi-Carmona, A. Le Duigou, D. Oustric, F. Barth, M. Bouaboula, P. Carayon, P. Casellas, and G. Le Fur Modulation of CB1 Cannabinoid Receptor Functions after a Long-Term Exposure to Agonist or Inverse Agonist in the Chinese Hamster Ovary Cell Expression System J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1038 - 1047. [Abstract] [Full Text]
|
|
|
|
|
|
W. Zhu, H. Friedman, and T. W. Klein Delta 9-Tetrahydrocannabinol Induces Apoptosis in Macrophages and Lymphocytes: Involvement of Bcl-2 and Caspase-1 J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1103 - 1109. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Ouyang, S. G. Hwang, S. H. Han, and N. E. Kaminski Suppression of Interleukin-2 by the Putative Endogenous Cannabinoid 2-Arachidonyl-Glycerol Is Mediated through Down-regulation of the Nuclear Factor of Activated T Cells Mol. Pharmacol., April 1, 1998; 53(4): 676 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
M. Rinaldi-Carmona, F. Barth, J. Millan, J.-M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, et al. SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 644 - 650. [Abstract] [Full Text]
|
|
|
|
|
|
M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS J. Biol. Chem., August 29, 1997; 272(35): 22330 - 22339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Valk, S. Verbakel, Y. Vankan, S. Hol, S. Mancham, R. Ploemacher, A. Mayen, B. Lowenberg, and R. Delwel Anandamide, a Natural Ligand for the Peripheral Cannabinoid Receptor Is a Novel Synergistic Growth Factor for Hematopoietic Cells Blood, August 15, 1997; 90(4): 1448 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Condie, A. Herring, W. S. Koh, M. Lee, and N. E. Kaminski Cannabinoid Inhibition of Adenylate Cyclase-mediated Signal Transduction and Interleukin 2 (IL-2) Expression in the Murine T-cell Line, EL4.IL-2 J. Biol. Chem., May 31, 1996; 271(22): 13175 - 13183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Xie, L. S. Melvin, and A. Makriyannis The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940 J. Biol. Chem., May 3, 1996; 271(18): 10640 - 10647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bayewitch, M.-H. Rhee, T. Avidor-Reiss, A. Breuer, R. Mechoulam, and Z. Vogel (-)-Delta^9-Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase J. Biol. Chem., April 26, 1996; 271(17): 9902 - 9905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bouaboula, B. Bourrié, M. Rinaldi-Carmona, D. Shire, Gér. L. Fur, and P. Casellas Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells J. Biol. Chem., June 9, 1995; 270(23): 13973 - 13980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Shire, C. Carillon, M. Kaghad, B. Calandra, M. Rinaldi-Carmona, Gér. Le Fur, D. Caput, and P. Ferrara An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing J. Biol. Chem., February 24, 1995; 270(8): 3726 - 3731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Mani, A. Mitchell, and B. W. O'Malley From the Cover: Progesterone receptor and dopamine receptors are required in Delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats PNAS, January 30, 2001; 98(3): 1249 - 1254. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
